Comparative Evaluation of the efficacy of Autologus melanocyte transfer along with PUVA therapy and PUVA therapy alone in vitiligo patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138706111159N1

Enrollment

Registered

2010-09-07

Start date

2007-08-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo. disorders of pigmentation

Interventions

Intervention 1: autologous melanocyte culture along with puva therapy. Intervention 2: puva therapy alone.

Treatment - Surgery

Treatment - Devices

autologous melanocyte culture along with puva therapy

puva therapy alone

Eligibility

Sex/Gender

All

Age

11 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: no treatment method since prior to 6 months ago, age 11-60, treatment history for 3 months Exclusion criteria: pregnancy, breast feeding, depigmented patch >5 squared cm, active vitiligo, infection on treated site, cloid history, Cobner reaction

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Repigmentation rate. Timepoint: 3 weeks, 3 months, 6 months after treatment. Method of measurement: perfect >90%, good 65-89%, moderate 25-64%, fair <25%.;Side effects. Timepoint: 3 weeks, 3 months, 6 months after treatment. Method of measurement: observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Ali Nilforoushzadeh

Skin Disease and Leishmaniasis Research Center, Isfahan University of Medical Sciences,

sdlrc@mui.ac.ir+98 31 1337 3736

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026